Skip to contentA
Arcturus Therapeutics Holdings Inc.
A
ARCTArcturus Therapeutics Holdings Inc. Released Nov 7, 2019, after the close
10-Q filed Nov 8, 2019, 39 days after period end · 0001564590-19-042017
Q3 2019 · 10-Q
Revenue$3.32M$3.32M−3.1% vs Q3 2018−67.3% vs Q2 2019 Net Income-$7.43M-$7.43M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcturus Therapeutics Holdings Inc. · CIK 1768224 · Engraved from SEC EDGAR
N/M vs Q2 2019
EPS Diluted-$0.56-$0.56N/M vs Q3 2018N/M vs Q2 2019 Operating Income-$7,616,000N/M Operating Cash Flowderived-$2,836,000N/M Free Cash Flowderived-$2,995,000N/M Margins · derivedOperating margin-229.5%−102.3 pt vs Q3 2018
Net margin-224.0%−99.8 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 8, 2019 · 39 d after period end